Blood-Based Alzheimer's and Neurodegeneration Test Developers
Commercial sector
Blood-Based Alzheimer's and Neurodegeneration Test Developers
Companies developing or offering blood tests specifically for Alzheimer's disease and related dementias, measuring analytes such as p-tau217, p-tau181, amyloid-beta 42/40 ratio, NfL, or GFAP for cognitive impairment screening, patient selection for disease-modifying therapies, or treatment monitoring. Includes LDT providers, IVD kit developers, and clinical laboratory services with validated AD blood panels.
Companies18
Commercial products143
Technology classes7
Countries9
Patents635
Profiled companies
Products
- RocheSwitzerland58
- ALZpathUnited States3
- Beckman CoulterUnited States24
- Diazyme LaboratoriesUnited States12
- Cx Precision MedicineUnited States3
- IBL InternationalGermany17
+ 12 more